{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+50%25+Intravenous+Solution", "query": { "intervention": "Dextrose 50% Intravenous Solution" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+50%25+Intravenous+Solution&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T04:35:59.791Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00136578", "title": "Ispinesib In Combination With Carboplatin In Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "SB-715992", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-10-20", "completion_date": "2006-10-25", "has_results": false, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136578" }, { "nct_id": "NCT01464593", "title": "Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer Liver Metastasis" ], "interventions": [ { "name": "Lyso-Thermosensitive Liposomal Doxorubicin", "type": "DRUG" }, { "name": "5% Dextrose Solution", "type": "OTHER" }, { "name": "ThermoDox", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2011-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2022-10-13", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 4, "location_summary": "Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464593" }, { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT05475210", "title": "177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-DOTA-EB-TATE", "type": "DRUG" }, { "name": "Amino Acid Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Molecular Targeting Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2022-06-18", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05475210" }, { "nct_id": "NCT00436553", "title": "Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Verteporfin Photodynamic Therapy", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Verteporfin Placebo", "type": "DRUG" }, { "name": "Ranibizumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 321, "start_date": "2007-02", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-04-19", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 36, "location_summary": "Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436553" }, { "nct_id": "NCT04500899", "title": "Use of Phenylephrine for Assessment of Mitral Regurgitation Severity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mitral Regurgitation" ], "interventions": [ { "name": "Mydfrin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-12-01", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04500899" }, { "nct_id": "NCT04291508", "title": "Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Respiratory Distress Syndrome", "Critical Illness", "Respiratory Failure", "Sepsis" ], "interventions": [ { "name": "Intravenous Acetaminophen (room temperature)", "type": "DRUG" }, { "name": "Intravenous Vitamin C (refrigerated)", "type": "DRUG" }, { "name": "5% Dextrose (room temperature)", "type": "DRUG" }, { "name": "5% Dextrose refrigerated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 488, "start_date": "2021-10-13", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291508" }, { "nct_id": "NCT07403604", "title": "Effect of Insulin Lowering on Lipogenesis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperinsulinemia", "Insulin Resistance", "Non-Alcoholic Fatty Liver Disease", "Prediabetic State", "Obesity" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Diazoxide Oral Suspension, 2 mg per kg per dose", "type": "DRUG" }, { "name": "Deuterated water (2H2O/D2O), 70%", "type": "DRUG" }, { "name": "Insulin Suppression Test (IST)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2026-07-01", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07403604" }, { "nct_id": "NCT00617981", "title": "Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "ThermoDox", "type": "DRUG" }, { "name": "5% Dextrose Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2008-05", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 9, "location_summary": "Los Angeles, California • Jacksonville, Florida • Louisville, Kentucky + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617981" }, { "nct_id": "NCT00244075", "title": "Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "nutritional supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "recombinant human growth hormone (rcGH)", "type": "DRUG" }, { "name": "exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "BEHAVIORAL" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 46, "start_date": "1998-07", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2015-05-25", "last_synced_at": "2026-09-20T04:35:59.791Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244075" } ] }